AB Science will be granted a patent, valid through 2040, covering the medical use of masitinib as a treatment for sickle cell ...

Jeanetta has been feeling poorly and never knew why until recently.

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders.

Mast cell activation syndrome, or disease (MCAS), is a condition that causes mast cells to release these substances too frequently, resulting in severe allergic reactions. After detecting an ...

According to the American College of Allergy Asthma and Immunology, nearly one in three U.S. adults report having a seasonal ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...